Approximately 14 million Americans are addicted to drugs and alcohol.The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity.Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction.Your firm - Drug Abuse Sciences (DAS) - is a notable exception.It has spent $190 million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $55 million today.Unfortunately, the firm's opportunity cost of funds is 9 percent and it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold. Expected (year-end) profits from selling the drug are presented in the accompanying table.

Year 1

Year 2

Year 3

Year 4

Year 5

Year 6

Year 7

Year 8

Year 9

$0

$0

$0

$0

$12,800,000

$14,200,000

$16,100,000

$18,600,000

$20,700,000

What is the net present value of the project?